Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000161-32
    Sponsor's Protocol Code Number:CLIN-52120-452
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-06-22
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2021-000161-32
    A.3Full title of the trial
    A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity
    Étude multicentrique, interventionnelle, post commercialisation, randomisée, en double aveugle, croisée visant à évaluer l’innocuité et l’efficacité cliniques de l’AbobotulinumtoxinA (Dysport®) par rapport à l’OnabotulinumtoxinA (Botox®) dans le traitement de patients adultes atteints de spasticité du membre supérieur
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults with Upper Limb Spasticity
    Étude visant à comparer l’innocuité et l’efficacité du Dysport® par rapport au Botox® dans le traitement de patients adultes atteints de spasticité du membre supérieur
    A.3.2Name or abbreviated title of the trial where available
    DIRECTION
    A.4.1Sponsor's protocol code numberCLIN-52120-452
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIpsen Pharma
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportIpsen Pharma
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIpsen Pharma
    B.5.2Functional name of contact pointRA Consultant – Neuroscience Global
    B.5.3 Address:
    B.5.3.1Street Address65 Quai Georges Gorse
    B.5.3.2Town/ cityBoulogne-Billancourt
    B.5.3.3Post code92100
    B.5.3.4CountryFrance
    B.5.4Telephone number314-704-1580
    B.5.6E-maildilani.dombagoda.ext@ipsen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dysport® 500 U powder for solution for injection
    D.2.1.1.2Name of the Marketing Authorisation holderIpsen Biopharm Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCLOSTRIDIUM BOTULINUM TOXIN TYPE A
    D.3.9.1CAS number 93384-43-1
    D.3.9.3Other descriptive nameBotulinum toxin type A
    D.3.9.4EV Substance CodeSUB77183
    D.3.10 Strength
    D.3.10.1Concentration unit U unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typetoxin
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Botox® 200 U powder for solution for injection
    D.2.1.1.2Name of the Marketing Authorisation holderAllergan Pharmaceuticals Ireland, a subsidiary of Allergan, Inc.
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCLOSTRIDIUM BOTULINUM TOXIN TYPE A
    D.3.9.1CAS number 93384-43-1
    D.3.9.3Other descriptive nameBotulinum toxin type A
    D.3.9.4EV Substance CodeSUB13117MIG
    D.3.10 Strength
    D.3.10.1Concentration unit U unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typetoxin
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    upper limb spasticity (ULS) of any aetiology (in US and France) or post-stroke ULS (in Canada)
    spasticité du membre supérieur (SMS) de toute étiologie (aux USA et en France) ou SMS postérieure à un accident vasculaire cérébral (au Canada)
    E.1.1.1Medical condition in easily understood language
    Upper limb spasticity is a medical condition when upper limb muscles are tight or in spasm and need to be relaxed.
    La spasticité du membre supérieur est une condition médicale dans laquelle les muscles dans membres supérieurs sont tendus ou contractés et ont besoin d'être relâchés
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To demonstrate non-inferiority as per safety assessment based on the rate of all TEAEs from injection to 12 weeks
    -Démontrer la non-infériorité selon l’évaluation de l’innocuité basée sur le taux de tous les EIAT entre l’injection et 12 semaines après l’injection
    E.2.2Secondary objectives of the trial
    - To evaluate clinical safety
    - To assess efficacy
    - Évaluer l’innocuité clinique
    - Évaluer l’efficacité
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Participant must be 18 to 75 years of age inclusive, at the time of signing the informed consent;
    2. 2a. [US/France] Participants with stable ULS for at least 3 months, in whom treatment of only one upper limb is necessary for the duration of the study;
    2b. [Canada] Participants with stable post-stroke ULS for at least 3 months, in whom treatment of only one upper limb is necessary for the duration of the study;
    3. Participants who are either naïve to BoNT-A for ULS or who have been previously treated with BoNT-A for ULS;
    4. Participants with MAS score of at least 2 at elbow, wrist and finger flexors;
    5. Participants with DAS score of at least 2 on the PTT (one of four functional domains: dressing, hygiene, limb position and pain);
    6. Participants who require BoNT-A injection in all of the following muscles: flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis and biceps brachii;
    7. Participants for whom injection of a total dose of 900 Units aboBoNT-A or 360 Units onaBoNT-A is considered by the investigator to be clinically appropriate;
    8. Participants who have been stable for at least 3 months prior to study entry in terms of oral antispasticity, anticoagulant and/or anticholinergic medication, if treated, and for at least 1 month prior to study entry in terms of occupational therapy and/or physiotherapy treatment, if treated, and are considered by the investigator likely to remain stable for the duration of the study;
    9. Male and female participants
    Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    a. Male participants:
    Male participants must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception. The participants must agree to use the contraception during the whole period of the study.
    b. Female participants:
    A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
    • Is a woman of non-childbearing potential, defined as postmenopausal for at least 1 year; surgical sterilisation at least 3 months before entering the study; or hysterectomy.
    or
    • Is a woman of childbearing potential (WOCBP) and using an acceptable
    contraceptive method as described in protocol section 10.4.2.
    A WOCBP must have a negative highly sensitive pregnancy test at screening (urine or serum) as required by local regulations.
    •If a urine test cannot be confirmed as negative (e.g. an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    10. Capable of giving signed informed consent as described in Section 10.1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    1. Le participant doit être âgé de 18 à 75 ans inclus au moment de la signature du consentement éclairé ;
    2. 2a. [États-Unis/France] Participants présentant une SMS stable depuis au moins 3 mois, pour lesquels le traitement d’un seul membre supérieur est nécessaire pendant la durée de l’étude ;
    2b. [Canada] Participants présentant une SMS postérieure à un accident vasculaire cérébral stable depuis au moins 3 mois, pour lesquels le traitement d’un seul membre supérieur est nécessaire pendant la durée de l’étude ;
    3. Participants n’ayant jamais reçu de BoNT-A pour traiter leur SMS ou ayant déjà reçu de la BoNT-A pour traiter leur SMS ;
    4. Participants présentant un score MAS d’au moins 2 au niveau des muscles fléchisseurs du coude, du poignet et des doigts ;
    5. Participants présentant un score DAS d’au moins 2 au niveau de la CPT (un des quatre domaines fonctionnels : habillage, hygiène, position des membres et douleurs) ;
    6. Participants nécessitant une injection de BoNT-A dans tous les muscles suivants : le muscle fléchisseur radial du carpe, le muscle fléchisseur antérieur du carpe, le muscle fléchisseur commun profond, le muscle fléchisseur commun superficiel et le biceps brachial ;
    7. Participants pour lesquels l’injection d’une dose totale de 900 unités d’aboBoNT-A ou de 360 unités d’onaBoNT-A est considérée par l’investigateur comme appropriée sur le plan clinique ;
    8. Participants ayant été stables pendant au moins 3 mois avant l’inclusion dans l’étude en termes de médicaments anti spasticité oraux, anticoagulants, et/ou anticholinergiques, s’ils étaient traités, et pendant au moins 1 mois avant l’inclusion dans l’étude en termes de traitement d’ergothérapie et/ou de physiothérapie, s’ils étaient traités, et étant considérés par l’investigateur comme susceptibles de rester stables pendant toute la durée de l’étude ;
    9. Hommes et femmes
    L’utilisation de contraceptifs par les hommes ou les femmes devra être conforme aux réglementations locales concernant les méthodes de contraception pour les patients participant à des études cliniques.
    a. Pour les hommes :
    Les hommes doivent accepter, si leur partenaire est susceptible de débuter une grossesse, d'utiliser une méthode de contraception efficace. Les participants doivent accepter d'utiliser la contraception pendant toute la durée de l'étude.
    b. Pour les femmes :
    Une femme est éligible à participer si elle n’est pas enceinte ou n’allaite pas et si au moins l’une des conditions suivantes s’applique :
    • Être une femme ne pouvant plus procréer, définie comme le fait d’être ménopausée depuis au moins 1 an ; avoir subi une stérilisation chirurgicale au moins 3 mois avant d’entrer dans l’étude ; ou avoir subi une hystérectomie.
    ou
    Être une femme en âge de procréer (FEAP) et utilisant une méthode de contraception acceptable comme décrit dans la Section 10.4.2.
    Une FEADP doit présenter un résultat d’un test de grossesse très sensible négatif lors de la sélection (urinaire ou sérique) comme l'exige la réglementation locale.
    • Si un résultat de test urinaire négatif ne peut pas être confirmé (p. ex., un résultat ambigu), un test de grossesse sérique est requis. Dans ce cas, la participante doit être exclue de l’étude si le résultat du test de grossesse sérique est positif.
    10. Être capables de donner un consentement éclairé signé comme décrit dans la Section 10.1, ce qui inclut le respect des exigences et des restrictions énumérées dans le formulaire de consentement éclairé (FCE) et dans ce protocole.
    E.4Principal exclusion criteria
    1. Major limitations in the passive range of motion in the paretic upper limb;
    2. Major neurological impairment (other than limb paresis) that could negatively affect functional performance;
    3. Participants clinically requiring injection into any upper limb muscles other than the five muscles of one arm listed in protocol section 5.1, or requiring injection into both arms or any lower limb within the timeframe of the study;
    4. Hypersensitivity to any BoNT product or excipients;
    5. Hypersensitivity to cow’s milk protein (casein);
    6. Infection at the proposed injection site(s);
    7. Known peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g. myasthenia gravis or Lambert-Eaton syndrome);
    8. Any medical condition (including dysphagia or breathing difficulties/compromised respiratory function) that, in the opinion of the investigator, might jeopardize the participant's safety;
    9. Abnormal screening/baseline findings or any other medical condition(s) that, in the opinion of the investigator, might jeopardise the participant’s safety;
    10. Women who are pregnant or lactating;
    11. In the clinical judgement of the investigator, BoNT treatment is inappropriate;
    12. Participants treated with BoNT of any type for any indication (e.g. bladder injection, headache or cosmetic) within the previous 12 weeks or planned/likely to be treated during the course of the study;
    13. Prior history of non-responsiveness to BoNT treatment;
    14. Previous surgery, or administration of alcohol or phenol in the study limb 6 months or earlier from study enrolment or planned/likely to be treated during the course of the study;
    15. Participants treated with intrathecal baclofen, aminoglycosides or other agents interfering with neuromuscular transmission (e.g. curare-like agents) within the previous 4 weeks or planned/likely to be treated during the course of the study;
    16. Participants who received a COVID-19 vaccine injection within 7 days before the first planned study intervention injection, or planned/likely to be vaccinated within 7 days after the first planned study intervention injection;
    17. Participants previously randomised for this study;
    18. Participants unwilling or unable to understand the nature, scope and possible consequences of the study and to comply with study procedures and requirements;
    19. Participants currently enrolled in any other clinical study or have participated in one within the 12 weeks prior to enrolment/inclusion visit, or are scheduled to receive a new investigational drug while the study is ongoing.
    1. Limitations majeures de l’amplitude des mouvements passifs du membre supérieur parétique ;
    2. Déficience neurologique majeure (autre que la parésie du membre) pouvant affecter négativement les performances fonctionnelles ;
    3. Participants nécessitant sur le plan clinique une injection dans tout muscle du membre supérieur autre que les cinq muscles d’un bras énumérés dans la section 5.1 ou nécessitant une injection dans les deux bras ou dans un membre inférieur pendant la période de l’étude ;
    4. Hypersensibilité à tout produit ou excipient de la BoNT ;
    5. Hypersensibilité aux protéines contenues dans le lait de vache (caséine) ;
    6. Infection au niveau du ou des sites d’injection proposés ;
    7. Maladies neuropathiques motrices périphériques connues, sclérose latérale amyotrophique ou troubles de la jonction neuromusculaire (p. ex., myasthénie grave ou syndrome de Lambert-Eaton) ;
    8. Tout problème médical (y compris une dysphagie ou des difficultés respiratoires/une altération de la fonction respiratoire) qui, selon l’investigateur, pourrait compromettre la sécurité du participant ;
    9. Résultats de sélection/d’inclusion anormaux ou tout autre problème médical qui, selon l’investigateur, pourrait compromettre la sécurité du participant ;
    10. Femmes enceintes ou qui allaitent ;
    11. Selon le jugement clinique de l’investigateur, un traitement par BoNT est inapproprié ;
    12. Participants ayant été traités par BoNT de tout type pour toute indication (p. ex., injection dans la vessie, maux de tête ou raison esthétique) au cours des 12 semaines précédentes ou ayant prévu/étant susceptibles d’être traités au cours de l’étude ;
    13. Antécédents d’absence de réponse au traitement par BoNT-A ;
    14. Participants ayant subi une chirurgie antérieure ou reçu de l’alcool ou du phénol dans le membre étudié 6 mois ou plus avant l’inclusion dans l’étude ou ayant prévu/étant susceptibles d’être traités au cours de l’étude ;
    15. Participants traités par baclofène intrathécal, des aminosides ou d’autres agents interférant avec la transmission neuromusculaire (p. ex., des agents de type curare), au cours des 4 semaines précédentes ou ayant prévu/étant susceptibles d’être traités au cours de l’étude ;
    16. Participants ayant reçu une injection du vaccin contre la COVID-19 au cours des 7 jours précédant la première injection prévue de l’intervention à l’étude, ou ayant prévu/étant susceptibles d’être vaccinés au cours des 7 jours suivant la première injection prévue de l’intervention à l’étude ;
    17. Participants ayant déjà été randomisés pour cette étude ;
    18. Participants ne souhaitant pas ou n’étant pas capables de comprendre la nature, la portée et les conséquences possibles de l’étude et de se conformer aux procédures et aux exigences de l’étude ;
    19. Participants actuellement inclus dans une autre étude clinique ou ayant participé à une étude clinique au cours des 12 semaines précédant la visite d’inclusion, ou ayant prévu de recevoir un nouveau médicament expérimental au cours de l’étude.
    E.5 End points
    E.5.1Primary end point(s)
    - Rate of TEAEs from injection to 12 weeks
    - Taux d’EIAT entre l’injection et 12 semaines après l’injection
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary safety endpoint is based on the TEAE incidence rate from injection to Week 12, i.e. TEAEs that occurred during each cycle from injection to 12 weeks after injection.
    Le critère d’évaluation principal de l’innocuité est basé sur le taux d’incidence des EIAT entre l’injection et la semaine 12, c’est-à-dire les EIAT survenus au cours de chaque cycle, entre l’injection et 12 semaines après l'injection.
    E.5.2Secondary end point(s)
    - Rate of ADRs, SAEs and AESIs from injection to 12 weeks
    - Duration of response based on retreatment criteria
    - Muscle tone assessed by the MAS for finger, wrist and elbow flexors at 1, 4, 10, 12 ± 16, 20, 24 weeks based on PTMG and MAS total score
    - Perceived function and pain assessed by the DAS at 1, 4, 10, 12 ± 16, 20, 24 weeks based on PTT and DAS total score
    - PGA of treatment response at 1, 4, 10, 12 ± 16, 20, 24 weeks
    - QoL, using the SF-12 perceived health score and SQoL-6D at 4 weeks, 12 weeks and at end of each cycle
    - Taux de RIM, d’EIG et d’EIIP entre l’injection et 12 semaines après l’injection
    - Durée de la réponse basée sur les critères de retraitement
    - Tonus musculaire évalué à l’aide de l’échelle MAS pour les muscles fléchisseurs des doigts, du poignet et du coude à 1, 4, 10, 12 ± 16, 20 et 24 semaines sur la base du score total du GMCP et de l’échelle MAS
    - Fonction et douleurs perçues évaluées à l’aide de l’échelle DAS à 1, 4, 10, 12 ± 16, 20 et 24 semaines sur la base du score total de la CPT et de l’échelle DAS
    - PGA de la réponse au traitement à 1, 4, 10, 12 ± 16, 20 et 24 semaines
    - QdV en utilisant le score de l’état de santé perçu du questionnaire SF-12 et le questionnaire SQoL-6D à 4 semaines, 12 semaines et à la fin de chaque cycle
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Rate of ADRs, SAEs and AESIs from injection to 12 weeks
    - The duration of response based on retreatment criteria - Descriptive statistics of the number and percentage of participants retreated from 12 weeks (Week 12, Week 16, Week 20, Week 24) will be provided.
    - Muscle tone assessed by the MAS for finger, wrist and elbow flexors at 1, 4, 10, 12 ± 16, 20, 24 weeks based on PTMG and MAS total score
    - Perceived function and pain assessed by the DAS at 1, 4, 10, 12 ± 16, 20, 24 weeks based on PTT and DAS total score
    - PGA of treatment response at 1, 4, 10, 12 ± 16, 20, 24 weeks
    - QoL, using the SF-12 perceived health score and SQoL-6D at 4 weeks, 12 weeks and at end of each cycle
    - Taux de RIM, d’EIG et d’EIIP entre l’injection et 12 semaines après l’injection
    - Durée de la réponse basée sur les critères de retraitement - Des statistiques descriptives du nombre et du pourcentage de participants retraités à partir de 12 semaines (12, 16, 20, 24 semaines) seront fournies
    - Tonus musculaire évalué à l’aide de l’échelle MAS pour les muscles fléchisseurs des doigts, du poignet et du coude à 1, 4, 10, 12 ± 16, 20 et 24 semaines sur la base du score total du GMCP et de l’échelle MAS
    -Fonction et douleurs perçues évaluées à l’aide de l’échelle DAS à 1, 4, 10, 12 ± 16, 20 et 24 semaines sur la base du score total de la CPT et de l’échelle DAS
    - PGA de la réponse au traitement à 1, 4, 10, 12 ± 16, 20 et 24 semaines
    - QdV en utilisant le score (etc...)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    France
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Dernière visite du dernier patient
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 423
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 141
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state72
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 72
    F.4.2.2In the whole clinical trial 564
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The participants will not receive any additional study intervention following the end of the study. Any further BoNT-A treatment after the end of the study will be at the investigator’s discretion with marketed product according to the approved local label.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-08-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-07-29
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 13:38:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA